Intellipharmaceutics Updates Status of Tentative Approvals

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)

TORONTO, June 18, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq: IPCI ) (TSX: I ) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the United States Food and Drug Administration ("FDA") has indicated that the Company's tentatively-approved strengths of its generic Focalin XR ® (dexmethylphenidate hydrochloride extended-release) capsules (the "Product") will have to meet newly-imposed conditions for bioequivalence prior to receiving final approval. The strengths affected are 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

The FDA, in November 2013, had previously granted the Company tentative approvals for the 5 mg, 10 mg, 20 mg, and 40 mg strengths of its generic Focalin XR ® . The Company is now required by the FDA to demonstrate bioequivalence with Focalin XR ® , under the new bioequivalence criteria, for the 40 mg strength as a basis for the approval of each of the affected strengths.

The Company, together with its United States commercialization partner, Par Pharmaceutical, Inc., intends to review and vigorously pursue all reasonable courses of action towards achieving final approval for each of the affected strengths. There can be no assurance that the affected strengths of the Product will be granted final FDA approval or sold commercially.

About Intellipharmaceutics

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications filed with the FDA (and one Abbreviated New Drug Submission filed with Health Canada) in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. Intellipharmaceutics also has New Drug Application 505(b)(2) product candidates in its development pipeline. These include Rexista™ Oxycodone XR, an abuse-deterrent oxycodone based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System and PODRAS™ Paradoxical OverDose Resistance Activating System, and Regabatin™ XR pregabalin extended-release capsules.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of developments or expenditures relating to our business, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "intends," "could," or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market conditions and other factors, including the current status of our product development programs, on capital availability, the potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities, our programs regarding research, development and commercialization of our product candidates, the timing of such programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our products and product candidates compared to our market estimates, our selection and licensing of products and product candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product sales, license agreements and other collaborative efforts for the development and commercialization of product candidates, our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell directly, the rate and degree of market acceptance of our products, the difficulty of predicting the impact of competitive products and pricing and the timing and success of product launches, the inability to forecast wholesaler demand and/or wholesaler buying patterns, the seasonal fluctuation in the numbers of prescriptions written for our dexmethylphenidate hydrochloride extended-release capsules which may produce substantial fluctuations in revenues, the timing and amount of insurance reimbursement for our products, changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other competing therapies that may become available, our ability to retain and hire qualified employees, the availability and pricing of third party sourced products and materials, difficulties or delays in manufacturing, the manufacturing capacity of third-party manufacturers that we may use for our products, and the successful compliance with FDA, Health Canada and other governmental regulations applicable to the Company and its third party manufacturers' facilities, products and/or businesses. Additional risks and uncertainties relating to the Company and our business can be found in the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the U.S., which are available on www.sedar.com and www.sec.gov . The forward-looking statements reflect our current views with respect to future events and are based on what we believe are reasonable assumptions as of the date of this document, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact: Intellipharmaceutics International Inc. Domenic Della Penna Chief Financial Officer 416-798-3001 ext 106 Investor Contact: ProActive Capital Kirin Smith 646-863-6519

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Customers Bancorp, Inc. Faces Class Action Lawsuit

Updated Category News Views 179

Introduction to the Class Action Lawsuit Against Customers Bancorp Recently, Customers Bancorp, Inc. found itself at the center of a significant legal challenge. A securities class action lawsuit has been initiated in federal court on behalf of investors who purchased or acquired shares of Customers Bancorp, Inc. (NYSE: CUBI) during a specific time frame. This action...

Continue Reading
Projected Growth in the Aluminum Beverage Can Industry

Updated Category News Views 238

Exploring the Future of the Aluminum Beverage Can Market As the aluminum beverage can industry steers toward a monumental future, it's evident that the market has grown significantly, evolving to meet the rising demand for sustainable and practical packaging solutions. With a valuation of US$ 36.95 billion in 2024, projections indicate a remarkable increase to US$ 61.12...

Continue Reading
Cybersecurity Initiative Launches for Global Nonprofit Protection

Updated Category News Views 87

Global Leaders Unite for Nonprofit Cybersecurity Influential figures from various sectors gathered at the historic Peace Palace to advocate for better cybersecurity within the nonprofit sector. This initiative, known as 'BEYOND125, Securing Our World's Digital Future,' is focused on tackling significant cybersecurity challenges faced by millions of organizations around...

Continue Reading
Guarda Wallet's Gas-Free USDT Revolution on Tron

Updated Category News Views 44

The Frictionless Future of USDT on the Tron Network You know, it seems like every few months we hear about some innovation that's going to 'revolutionize' crypto transactions. But here's something that's actually shifting the gears—a practical workaround for a typical problem faced by the average Joe trading in stablecoins. Welcome to Guarda Wallet's gas-free...

Continue Reading
Ultragenyx and Mereo BioPharma Stocks Face Significant Decline

Updated Category News Views 130

Overview of Current Situation Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) saw their stock values significantly drop recently, causing concern among investors. The decline comes in light of new developments from their ongoing clinical trials for a drug targeting a rare genetic disorder. What Unfolded? The duo announced updates...

Continue Reading